Skip to content
10-Q

Quarterly Report

Revance Therapeutics, Inc.

0001479290-24-000128

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 104.9M sh
Shares Diluted Q3 2024 · Sep 30, 2024 104.21M sh
Shares Diluted Q3 2024 · Sep 30, 2024 100.02M sh
Shares Diluted Q3 2024 · Sep 30, 2023 86.61M sh
Shares Diluted Q3 2024 · Sep 30, 2023 83.82M sh
Capex Q3 2024 · Sep 30, 2024 $2.24M
Capex Q3 2024 · Sep 30, 2023 $5.11M
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$148.16M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$173.84M
Long Term Debt Q3 2024 · Sep 30, 2024 $421.04M
Long Term Debt Q3 2024 · Dec 31, 2023 $426.6M
Short Term Debt Q3 2024 · Sep 30, 2024 $10.15M
Short Term Debt Q3 2024 · Dec 31, 2023 $2.5M
Short Term Investments Q3 2024 · Sep 30, 2024 $125.49M
Short Term Investments Q3 2024 · Dec 31, 2023 $116.59M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $58.59M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $137.33M
Stockholders Equity Q3 2024 · Sep 30, 2024 −$163.03M
Stockholders Equity Q3 2024 · Dec 31, 2023 −$151.6M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$106.2M
Current Liabilities Q3 2024 · Sep 30, 2024 $80.05M
Current Liabilities Q3 2024 · Dec 31, 2023 $89.22M
Total Liabilities Q3 2024 · Sep 30, 2024 $624.59M
Total Liabilities Q3 2024 · Dec 31, 2023 $630.06M
Current Assets Q3 2024 · Sep 30, 2024 $329.69M
Current Assets Q3 2024 · Dec 31, 2023 $338.87M
Total Assets Q3 2024 · Sep 30, 2024 $461.56M
Total Assets Q3 2024 · Dec 31, 2023 $478.45M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.37
Eps Diluted Q3 2024 · Sep 30, 2024 −$1.29
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.63
Eps Diluted Q3 2024 · Sep 30, 2023 −$3.20
Eps Basic Q3 2024 · Sep 30, 2024 −$0.37
Eps Basic Q3 2024 · Sep 30, 2024 −$1.29
Eps Basic Q3 2024 · Sep 30, 2023 −$1.63
Eps Basic Q3 2024 · Sep 30, 2023 −$3.20
Sga Expense Q3 2024 · Sep 30, 2024 $62.58M
Sga Expense Q3 2024 · Sep 30, 2024 $197.31M
Sga Expense restated Q3 2024 · Sep 30, 2023 $65.79M
Sga Expense restated Q3 2024 · Sep 30, 2023 $202.52M
Rd Expense Q3 2024 · Sep 30, 2024 $11.38M
Rd Expense Q3 2024 · Sep 30, 2024 $41.67M
Rd Expense restated Q3 2024 · Sep 30, 2023 $8.69M
Rd Expense restated Q3 2024 · Sep 30, 2023 $43.84M
Net Income Q3 2024 · Sep 30, 2024 −$38.12M
Net Income Q3 2024 · Sep 30, 2024 −$128.74M
Net Income Q3 2024 · Sep 30, 2023 −$141.18M
Net Income Q3 2024 · Sep 30, 2023 −$268.29M
Operating Income Q3 2024 · Sep 30, 2024 −$32.26M
Operating Income Q3 2024 · Sep 30, 2024 −$113.6M
Operating Income restated Q3 2024 · Sep 30, 2023 −$37.56M
Operating Income restated Q3 2024 · Sep 30, 2023 −$140.62M
Revenue Q3 2024 · Sep 30, 2024 $59.88M
Revenue Q3 2024 · Sep 30, 2024 $177.2M
Revenue restated Q3 2024 · Sep 30, 2023 $54.11M
Revenue restated Q3 2024 · Sep 30, 2023 $154.3M